Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Mechanistic Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Orally Administered Epeleuton in Patients With Sickle Cell Disease

NCT05861453 is registered in ClinicalTrials.gov with Afimmune as lead sponsor.

NCT NCT05861453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05861453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Mechanistic Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Orally Administered Epeleuton in Patients With Sickle Cell Disease
Lead sponsor
Afimmune
Phase
Phase 2
Overall status
Completed
Start date
January 10, 2024
Completion date
February 11, 2026
Enrollment
35 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease